諾瓦瓦克斯醫藥
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About 諾瓦瓦克斯醫藥
Novavax, Inc. 是一家生物技術公司，專注於疫苗的發現、開發和商業化，以預防嚴重的傳染病和滿足健康需求。公司的候選疫苗包括 NVX-CoV2373，一種冠狀病毒候選疫苗，正在進行兩項 III 期試驗、一項 IIb 期試驗和一項 I/II 期試驗； NanoFlu，一種納米顆粒季節性四價流感候選疫苗，正在進行 3 期臨床試驗；和 ResVax，一種呼吸道合胞病毒 (RSV) 融合 (F) 蛋白納米顆粒候選疫苗。它還正在開發針對老年人（60 歲及以上）的 II 期臨床試驗以及針對兒科的 I 期臨床試驗的 RSV F 疫苗。它與 Takeda Pharmaceutical Company Limited 就 COVID-19候選疫苗 NVX-CoV2373的開發、製造和商業化達成了合作協議。 Novavax, Inc. 成立於 1987 年，總部位於馬里蘭州蓋瑟斯堡。
如何購買 諾瓦瓦克斯醫藥 (NVAX)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 NVAX
透過 RockFlow App 或網頁端搜尋 NVAX，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.